We help your Medical Affairs department access qualitative and traceable RWE. At scale.

Tired of doubting your data's quality? Overwhelmed by the challenge of integrating disparate data sources? Are data governance and legal concerns slowing down your decision-making process?

Imagine having hassle-free access to robust and granular RWE you can trust.

At LynxCare, we free you to focus on what matters most – driving insights and advancing healthcare.

Download our use-case folder

8 Top 20 Pharmaceutical companies already trust the LynxCare platform
J&J logo
Bayer logo
Pfizer logo
Boehringer logo
Novartis logo
Novartis logo
MSD logo
J&J logo
AstraZeneca Logo

Get inspired by some of our use cases.

  • Unlocking Real-World Evidence about Immune Checkpoint Inhibitor Treatment in Diverse Cancer Types
  • Real-World Eligibility for Dapagliflozin Treatment in Unselected Heart Failure Patients: Data from the Heart Failure Registry
  • Detection of cardiac aTTR amyloidosis in a real-world heart failure population: automated data extraction from electronic health records using Natural Language Processing
  • An Artificial Intelligence-driven framework to screen for hATTR polyneuropathy by automatically detecting red flag symptoms in Electronic Health Records
Download the presentation folder
LynxCare use case presentation folder

Why life science organisations choose LynxCare

hospital icon

Unlock a previously untapped source of RWE

  • Unlock the full potential of siloed and unstructured hospital data using AI & Natural Language Processing
NLP and NTL icon

Guaranteed data quality & traceability

  • LynxCare provides data quality and data traceability guarantees. So HCPs and hospital researchers can rely on and check data quality at all times.
  • The mined data is first validated by experts, and has an accuracy of >90%.
RWE collab orations icon

Secure collaborations under a federated model

  • A federated AI data model ensures all data remains under the custody of the hospital or registry.
Benchmarking icon

Benchmark across institutes and data sets

  • Compare data sets across regions, institutes, languages and therapeutic areas.
Cost efficient RWE logo

Cost-efficient RWE insights

  • Reduce time spent on validating data sets by deploying artificial intelligence to do the extraction.
HCP relations logo

Solidify your relations with healthcare organizations

  • Use the value-add LynxCare provides to healthcare organizations to establish a long-term relationship.

Drive health innovation with RWE

Improving quality of care through RWE collaborations

Improving the quality of care through RWE collaborations.

RWE has the power to change lives. It can allow for new treatments to come to market faster, but most importantly it provides valuable insight on how they perform where it really counts: real life.

To harness the full potential of RWE for treatment optimisation and research, we need to unlock the most critical data scource: hospital data.

Insights generated by RWE are only as qualitative as the data source.

In the past, the siloed nature of hospital systems and privacy concerns served as a major bottleneck for it’s inclusion in RWE generation strategies.

As a result, traditional RWE generation efforts relied on accessible but sub-par data sources, leading to data relevance issues and incomplete datasets. The only resort used to be chart review and Observational studies, which are in many cases prohibitively expensive.

RWE report data accessibility graph
Actionable RWD visual

We help you generate the RWE you need by making RWD actionable

Currently, only around 20% of hospital data is used for outcomes improvement and research. The remaining 80% is scattered and unstructured. As a result, this data is not available for research collaborations with other stakeholders.

LynxCare helps hospitals harmonize and aggregate their structured & unstructured data into a clinical grade OMOP data warehouse, unlocking a previously untapped source of RWD.

Data governance matters.

LynxCare was founded from an individual patient's need. Securing patient's interest is at our core. We are convinced data should also serve a bigger scientific purpose so it can help new treatments and other patients, however never purely commercial interests.

As such, LynxCare advocates for clear data governance structures (i.e. ethical and data committees) that science and patient's interests are safeguarded. With proper data governance in place, trust in data is ensured, so stakeholders can collaborate efficiently.

Data governance visual
RWE federated learning model visual

Say goodbye to privacy concerns. Say hello to multi-center RWE studies.

As the hospital remains in control of the data, it can be made available for research collaborations with the Life Sciences industry - without transfer of data ownership. This is the concept of a federated approach, as shared by the European Health Data and Evidence Network.

Additionally, data stored in OMOP format adheres to the FAIR data principle. This allows Hospitals to participate in federated data networks, enabling multi-center, multi-stakeholder RWE collaborations.

We've got you covered.

Compliance excellence.

Privacy by design. Secure Infrastructure. Federated network.

LynxCare maintains the highest ethical standards and is compliant with (inter)national privacy regulations in both the EU and the USA. We enable scientific - not commercial - research within a federated data infrastructure.
ISO 27001:2017GDPR logoEHDEN logoHIPPA logoNEN 7510-1:2017

Have a specific use case in mind? Talk to an expert.

Deployed over many therapeutic domains

Immuno-Oncology

Clinical Context
Cohort
No items found.

Oncology

Clinical Context
Cohort
Breast cancer
Breast cancer
Hemato-oncology
Chronic lymphocytic leukemia (CLL)
Lung cancer
Lung cancer
Immuno-oncology
Immuno-oncology
Hemato-oncology
Multiple myeloma

Cardiology

Clinical Context
Cohort
Heart Failure
Heart failure
Atrial Fibrillation
Atrial Fibrillation

Rare diseases

Clinical Context
Cohort
Rare diseases
ATTR-CM
Rare diseases
TTR-FAP

Hematology

Clinical Context
Cohort
Hemato-oncology
Chronic lymphocytic leukemia (CLL)
Hemato-oncology
Multiple myeloma